Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Dupont

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
Heart Rhythm|August 28, 2017
Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiologyPieter Martens, Petra Nijst, Frederik H Verbrugge, et al.
International Journal of Cardiology|May 27, 2017
Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implicationsPetra Nijst, Frederik H Verbrugge, Pieter Martens, et al.
Circulation. Heart Failure|July 20, 2014
Urinary composition during decongestive treatment in heart failure with reduced ejection fractionFrederik H Verbrugge, Petra Nijst, Matthias Dupont, et al.
Journal of Cardiovascular Translational Research|February 27, 2020
Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection FractionPetra Nijst, Pieter Martens, Frederik H Verbrugge, et al.
Acta Cardiologica|November 8, 2019
Determinants of maximal dose titration of sacubitril/valsartan in clinical practicePieter Martens, Lina Verluyten, Heleen Van de Broek, et al.
ESC Heart Failure|September 29, 2019
Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapyPieter Martens, Matthias Dupont, Jeroen Dauw, et al.
European Journal of Heart Failure|January 5, 2013
Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatmentMatthias Dupont, Wilfried Mullens, Michael Finucan, et al.
Clinical Cardiology|September 10, 2019
Implications of renin-angiotensin-system blocker discontinuation in acute decompensated heart failure with systolic dysfunctionDouglas Darden, Mark H Drazner, Wilfried Mullens, et al.
The American Journal of Cardiology|November 30, 2013
Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractionsFrederik H Verbrugge, Jürgen Duchenne, Philippe B Bertrand, et al.
Microcirculation (New York, N.Y. : 1994)|December 7, 2017
Endovascular shedding markers in patients with heart failure with reduced ejection fraction: Results from a single-center exploratory studyPetra Nijst, Jirka Cops, Pieter Martens, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Heart Rhythm|August 28, 2017
Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiologyPieter Martens, Petra Nijst, Frederik H Verbrugge, et al.
International Journal of Cardiology|May 27, 2017
Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implicationsPetra Nijst, Frederik H Verbrugge, Pieter Martens, et al.
Circulation. Heart Failure|July 20, 2014
Urinary composition during decongestive treatment in heart failure with reduced ejection fractionFrederik H Verbrugge, Petra Nijst, Matthias Dupont, et al.
Journal of Cardiovascular Translational Research|February 27, 2020
Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection FractionPetra Nijst, Pieter Martens, Frederik H Verbrugge, et al.
Acta Cardiologica|November 8, 2019
Determinants of maximal dose titration of sacubitril/valsartan in clinical practicePieter Martens, Lina Verluyten, Heleen Van de Broek, et al.
ESC Heart Failure|September 29, 2019
Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapyPieter Martens, Matthias Dupont, Jeroen Dauw, et al.
European Journal of Heart Failure|January 5, 2013
Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatmentMatthias Dupont, Wilfried Mullens, Michael Finucan, et al.
Clinical Cardiology|September 10, 2019
Implications of renin-angiotensin-system blocker discontinuation in acute decompensated heart failure with systolic dysfunctionDouglas Darden, Mark H Drazner, Wilfried Mullens, et al.
The American Journal of Cardiology|November 30, 2013
Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractionsFrederik H Verbrugge, Jürgen Duchenne, Philippe B Bertrand, et al.
Microcirculation (New York, N.Y. : 1994)|December 7, 2017
Endovascular shedding markers in patients with heart failure with reduced ejection fraction: Results from a single-center exploratory studyPetra Nijst, Jirka Cops, Pieter Martens, et al.
Pageof 13